Analyzing Omnicell (NASDAQ:OMCL) & Mitesco (OTCMKTS:MITI)

Omnicell (NASDAQ:OMCL) and Mitesco (OTCMKTS:MITI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Profitability

This table compares Omnicell and Mitesco’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Omnicell	0.17%	3.00%	1.81%
Mitesco	-7,638.20%	N/A	-2,270.77%

Analyst Recommendations

This is a breakdown of current recommendations for Omnicell and Mitesco, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	1	1	6	0	2.63
Mitesco	0	0	0	0	0.00

Omnicell currently has a consensus target price of $58.50, suggesting a potential upside of 72.36%. Given Omnicell’s stronger consensus rating and higher probable upside, research analysts clearly believe Omnicell is more favorable than Mitesco.

Valuation & Earnings

This table compares Omnicell and Mitesco”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18 billion	1.30	$2.05 million	$0.04	848.50
Mitesco	$40,000.00	38.97	-$2.51 million	($0.14)	-0.64

Omnicell has higher revenue and earnings than Mitesco. Mitesco is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 0.0% of Mitesco shares are owned by institutional investors. 2.5% of Omnicell shares are owned by company insiders. Comparatively, 4.9% of Mitesco shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Omnicell has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Mitesco has a beta of 5.49, indicating that its stock price is 449% more volatile than the S&P 500.

Summary

Omnicell beats Mitesco on 11 of the 14 factors compared between the two stocks.

About Omnicell

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

About Mitesco

Mitesco, Inc. does not have significant operations. Previously, it was engaged in healthcare technology and services business. Mitesco, Inc. is based in Vero Beach, Florida.